{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:00Z","timestamp":1791593820686,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.imlet.2012.01.005","type":"journal-article","created":{"date-parts":[[2012,1,29]],"date-time":"2012-01-29T00:22:16Z","timestamp":1327796536000},"page":"146-151","source":"Crossref","is-referenced-by-count":5,"title":["Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1"],"prefix":"10.1016","volume":"143","author":[{"given":"Wei","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2012.01.005_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.imlet.2012.01.005_bib0010","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1007\/BF01540895","article-title":"Inflammatory neuropathies\u2014pathogenesis and the role of intravenous immune globulin","volume":"15","author":"van der Mech\u00e9","year":"1995","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain\u2013Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency","volume":"12","author":"Oczko-Walker","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.imlet.2012.01.005_bib0020","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archneurol.2011.137","article-title":"Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy","volume":"68","author":"Lin","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000109932","article-title":"Intravenous polyclonal human immunoglobulins in multiple sclerosis","volume":"5","author":"Soelberg Sorensen","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.imlet.2012.01.005_bib0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2012.01.005_bib0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3810\/pgm.2010.09.2214","article-title":"The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins","volume":"122","author":"Stein","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.imlet.2012.01.005_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0165-5728(01)00266-1","article-title":"Multifocal motor neuropathy","volume":"115","author":"Nobile-Orazio","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0045","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1093\/brain\/awf258","article-title":"Localization of major gangliosides in the PNS: implications for immune neuropathies","volume":"125","author":"Gong","year":"2002","journal-title":"Brain"},{"issue":"Pt 3","key":"10.1016\/j.imlet.2012.01.005_bib0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/brain\/122.3.449","article-title":"The distribution of ganglioside-like moieties in peripheral nerves","volume":"122","author":"Sheikh","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.imlet.2012.01.005_bib0055","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/glia.20503","article-title":"Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers","volume":"55","author":"Susuki","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.imlet.2012.01.005_bib0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ana.410370405","article-title":"Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers","volume":"37","author":"Takigawa","year":"1995","journal-title":"Ann Neurol"},{"issue":"Pt 12","key":"10.1016\/j.imlet.2012.01.005_bib0065","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/brain\/120.12.2159","article-title":"The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons","volume":"120","author":"Hirota","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.imlet.2012.01.005_bib0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/glycob\/6.6.581","article-title":"Anti-idiotypic monoclonal antibodies to GM1 identify ganglioside binding proteins","volume":"6","author":"Riggott","year":"1996","journal-title":"Glycobiology"},{"key":"10.1016\/j.imlet.2012.01.005_bib0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/mp900241t","article-title":"The mechanism of polyplex internalization into cells: testing the GM1\/Caveolin-1 lipid raft mediated endocytosis pathway","volume":"7","author":"Qi","year":"2010","journal-title":"Mol Pharmaceut"},{"key":"10.1016\/j.imlet.2012.01.005_bib0080","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1074\/jbc.273.18.11205","article-title":"Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture","volume":"273","author":"Kopitz","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.imlet.2012.01.005_bib0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2010.03.010","article-title":"Activation of RAW264.7 macrophages by oxidized galectin-1","volume":"131","author":"Echigo","year":"2010","journal-title":"Immunol Lett"},{"key":"10.1016\/j.imlet.2012.01.005_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/hep.24294","article-title":"Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization and in vivo tumor growth","author":"Espelt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.imlet.2012.01.005_bib0095","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.4049\/jimmunol.1000715","article-title":"Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation","volume":"185","author":"Cedeno-Laurent","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0076-6879(10)80011-4","article-title":"Multiple functional targets of the immunoregulatory activity of galectin-1: control of immune cell trafficking, dendritic cell physiology, and T-cell fate","volume":"480","author":"Cooper","year":"2010","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410390121","article-title":"Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen","volume":"39","author":"Malik","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0165-5728(99)00276-3","article-title":"Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies","volume":"105","author":"Lopez","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jneuroim.2010.08.023","article-title":"IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN","volume":"229","author":"Piepers","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp.2010.205856","article-title":"IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy","volume":"82","author":"Yuki","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.imlet.2012.01.005_bib0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(96)00053-6","article-title":"Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies","volume":"139","author":"Yuki","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.imlet.2012.01.005_bib0130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jnnp.62.4.391","article-title":"Long term follow up of multifocal motor neuropathy with conduction block under treatment","volume":"62","author":"Azulay","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.imlet.2012.01.005_bib0135","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1528-1157.1996.tb00527.x","article-title":"Cryptogenic partial epilepsies with anti-GM1 antibodies: a new form of immune-mediated epilepsy?","volume":"37","author":"Bartolomei","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.imlet.2012.01.005_bib0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0165-5728(91)90192-A","article-title":"Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera","volume":"32","author":"Adams","year":"1991","journal-title":"J Neuroimmunol"},{"issue":"Suppl. 1","key":"10.1016\/j.imlet.2012.01.005_bib0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.1996.104.s1.3","article-title":"Mechanisms of action of intravenous immune globulin in immune-mediated diseases","volume":"104","author":"Mouthon","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","article-title":"Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies","volume":"231","author":"Lehmann","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/08820130009060871","article-title":"Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations","volume":"29","author":"Terryberry","year":"2000","journal-title":"Immunol Invest"},{"key":"10.1016\/j.imlet.2012.01.005_bib0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-510X(01)00580-9","article-title":"Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain\u2013Barre syndrome","volume":"190","author":"Press","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.imlet.2012.01.005_bib0165","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/jaut.1993.1057","article-title":"Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg","volume":"6","author":"Masson","year":"1993","journal-title":"J Autoimmun"},{"key":"10.1016\/j.imlet.2012.01.005_bib0170","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood.V98.10.3136","article-title":"Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect","volume":"98","author":"Bleeker","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2012.01.005_bib0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clim.2010.05.006","article-title":"Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency","volume":"136","author":"Freiberger","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/clin.1995.1148","article-title":"Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases","volume":"77","author":"Krause","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0185","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.1012","article-title":"Animal model of axonal Guillain\u2013Barre syndrome induced by sensitization with GM1 ganglioside","volume":"49","author":"Yuki","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0190","doi-asserted-by":"crossref","first-page":"829129","DOI":"10.1155\/2011\/829129","article-title":"Guillain\u2013Barre syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder","volume":"2011","author":"Shahrizaila","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000111916","article-title":"Immunohistochemical localization of a beta-galactoside-binding lectin in rat central nervous system. I. Light- and electron-microscopical studies on developing cerebral cortex and corpus callosum","volume":"11","author":"Joubert","year":"1989","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.imlet.2012.01.005_bib0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s004180050444","article-title":"Immunohistochemical distribution of galectin-1, galectin-3, and olfactory marker protein in human olfactory epithelium","volume":"113","author":"Heilmann","year":"2000","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.neuroscience.2010.05.001","article-title":"Trajectory and terminal distribution of single centrifugal axons from olfactory cortical areas in the rat olfactory bulb","volume":"169","author":"Matsutani","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.imlet.2012.01.005_bib0210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1389450054021954","article-title":"Oxidized galectin-1 is an essential factor for peripheral nerve regeneration","volume":"6","author":"Horie","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.imlet.2012.01.005_bib0215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0165-2478(99)00012-7","article-title":"Galectin-1, a natural ligand for the receptor-type protein tyrosine phosphatase CD45","volume":"67","author":"Walzel","year":"1999","journal-title":"Immunol Lett"},{"key":"10.1016\/j.imlet.2012.01.005_bib0220","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.4049\/jimmunol.165.5.2331","article-title":"CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death","volume":"165","author":"Pace","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00418-009-0597-x","article-title":"Galectin-1 induced activation of the mitochondrial apoptotic pathway: evidence for a connection between death-receptor and mitochondrial pathways in human Jurkat T lymphocytes","volume":"132","author":"Lange","year":"2009","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0230","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4049\/jimmunol.162.2.799","article-title":"Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation","volume":"162","author":"Vespa","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0235","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2010.07.015","article-title":"A novel galectin-1 and interleukin 2 receptor beta haplotype is associated with autoimmune myasthenia gravis","volume":"229","author":"Pal","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0240","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(01)00243-0","article-title":"Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis","volume":"114","author":"Aktas","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trim.2010.04.009","article-title":"Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction","volume":"23","author":"Sharma","year":"2010","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0250","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2008.089292","article-title":"Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis","volume":"68","author":"Van Beneden","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2012.01.005_bib0255","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.4049\/jimmunol.163.10.5427","article-title":"Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells","volume":"163","author":"Dong","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2012.01.005_bib0260","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1073\/pnas.0702936104","article-title":"Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity","volume":"104","author":"Nimmerjahn","year":"2007","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247812000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247812000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T03:12:19Z","timestamp":1686712339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247812000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0165247812000077"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2012.01.005","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}